vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and OHIO VALLEY BANC CORP (OVBC). Click either name above to swap in a different company.

OHIO VALLEY BANC CORP is the larger business by last-quarter revenue ($16.2M vs $13.5M, roughly 1.2× Assertio Holdings, Inc.). On growth, OHIO VALLEY BANC CORP posted the faster year-over-year revenue change (-4.6% vs -57.9%). Over the past eight quarters, OHIO VALLEY BANC CORP's revenue compounded faster (4.3% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Valley National Bank of Arizona was a bank based in Phoenix, Arizona, founded in 1900 and acquired by Bank One in 1992. The bank was one of Arizona's leading financial institutions during the 20th century and the last major independent bank in Arizona at the time of its acquisition.

ASRT vs OVBC — Head-to-Head

Bigger by revenue
OVBC
OVBC
1.2× larger
OVBC
$16.2M
$13.5M
ASRT
Growing faster (revenue YoY)
OVBC
OVBC
+53.3% gap
OVBC
-4.6%
-57.9%
ASRT
Faster 2-yr revenue CAGR
OVBC
OVBC
Annualised
OVBC
4.3%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
OVBC
OVBC
Revenue
$13.5M
$16.2M
Net Profit
$4.0M
Gross Margin
Operating Margin
-86.7%
30.7%
Net Margin
24.4%
Revenue YoY
-57.9%
-4.6%
Net Profit YoY
57.3%
EPS (diluted)
$-4.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
OVBC
OVBC
Q4 25
$13.5M
$16.2M
Q3 25
$49.5M
$16.3M
Q2 25
$29.2M
$17.4M
Q1 25
$26.5M
$16.8M
Q4 24
$32.2M
$17.0M
Q3 24
$29.2M
$15.4M
Q2 24
$31.1M
$14.7M
Q1 24
$32.4M
$14.9M
Net Profit
ASRT
ASRT
OVBC
OVBC
Q4 25
$4.0M
Q3 25
$11.4M
$3.0M
Q2 25
$-16.4M
$4.2M
Q1 25
$-13.5M
$4.4M
Q4 24
$2.5M
Q3 24
$-2.9M
$2.7M
Q2 24
$-3.7M
$3.0M
Q1 24
$-4.5M
$2.8M
Operating Margin
ASRT
ASRT
OVBC
OVBC
Q4 25
-86.7%
30.7%
Q3 25
23.2%
22.9%
Q2 25
-27.5%
29.8%
Q1 25
-50.0%
33.1%
Q4 24
-41.9%
18.1%
Q3 24
-10.4%
21.3%
Q2 24
-11.6%
24.7%
Q1 24
-13.4%
22.8%
Net Margin
ASRT
ASRT
OVBC
OVBC
Q4 25
24.4%
Q3 25
23.1%
18.5%
Q2 25
-56.0%
24.2%
Q1 25
-51.1%
26.2%
Q4 24
14.8%
Q3 24
-10.0%
17.6%
Q2 24
-11.8%
20.3%
Q1 24
-13.9%
18.8%
EPS (diluted)
ASRT
ASRT
OVBC
OVBC
Q4 25
$-4.54
Q3 25
$0.11
Q2 25
$-0.17
Q1 25
$-0.14
Q4 24
$-3.28
Q3 24
$-0.03
Q2 24
$-0.04
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
OVBC
OVBC
Cash + ST InvestmentsLiquidity on hand
$63.4M
$45.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$170.3M
Total Assets
$267.0M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
OVBC
OVBC
Q4 25
$63.4M
$45.9M
Q3 25
$93.4M
$89.3M
Q2 25
$98.2M
$54.6M
Q1 25
$87.3M
$120.6M
Q4 24
$100.1M
$83.1M
Q3 24
$88.6M
$82.2M
Q2 24
$88.4M
$107.7M
Q1 24
$80.7M
$129.1M
Total Debt
ASRT
ASRT
OVBC
OVBC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
OVBC
OVBC
Q4 25
$94.0M
$170.3M
Q3 25
$105.8M
$164.4M
Q2 25
$93.3M
$160.8M
Q1 25
$108.5M
$155.7M
Q4 24
$121.1M
$150.3M
Q3 24
$130.5M
$152.2M
Q2 24
$132.2M
$145.8M
Q1 24
$134.5M
$145.8M
Total Assets
ASRT
ASRT
OVBC
OVBC
Q4 25
$267.0M
$1.6B
Q3 25
$319.8M
$1.6B
Q2 25
$273.8M
$1.5B
Q1 25
$286.4M
$1.5B
Q4 24
$284.7M
$1.5B
Q3 24
$276.0M
$1.5B
Q2 24
$279.4M
$1.4B
Q1 24
$282.0M
$1.4B
Debt / Equity
ASRT
ASRT
OVBC
OVBC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
OVBC
OVBC
Operating Cash FlowLast quarter
$-30.0M
$18.1M
Free Cash FlowOCF − Capex
$17.0M
FCF MarginFCF / Revenue
105.2%
Capex IntensityCapex / Revenue
6.4%
Cash ConversionOCF / Net Profit
4.57×
TTM Free Cash FlowTrailing 4 quarters
$26.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
OVBC
OVBC
Q4 25
$-30.0M
$18.1M
Q3 25
$-4.8M
$5.3M
Q2 25
$19.1M
$4.5M
Q1 25
$-12.5M
$496.0K
Q4 24
$11.5M
$13.1M
Q3 24
$-35.0K
$5.6M
Q2 24
$7.4M
$4.2M
Q1 24
$7.5M
$928.0K
Free Cash Flow
ASRT
ASRT
OVBC
OVBC
Q4 25
$17.0M
Q3 25
$5.0M
Q2 25
$4.4M
Q1 25
$138.0K
Q4 24
$11.7M
Q3 24
$5.4M
Q2 24
$3.9M
Q1 24
$234.0K
FCF Margin
ASRT
ASRT
OVBC
OVBC
Q4 25
105.2%
Q3 25
30.4%
Q2 25
25.1%
Q1 25
0.8%
Q4 24
68.7%
Q3 24
35.1%
Q2 24
26.3%
Q1 24
1.6%
Capex Intensity
ASRT
ASRT
OVBC
OVBC
Q4 25
6.4%
Q3 25
2.1%
Q2 25
0.6%
Q1 25
2.1%
Q4 24
8.4%
Q3 24
0.0%
1.2%
Q2 24
2.2%
Q1 24
4.7%
Cash Conversion
ASRT
ASRT
OVBC
OVBC
Q4 25
4.57×
Q3 25
-0.42×
1.75×
Q2 25
1.06×
Q1 25
0.11×
Q4 24
5.21×
Q3 24
2.06×
Q2 24
1.41×
Q1 24
0.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

OVBC
OVBC

Segment breakdown not available.

Related Comparisons